SCHEMBL2909927

SCHEMBL2909927

CC(C)(C)OC(=O)c1cn(CCCCNc2ccc([N+](=O)[O-])c(N)n2)cc1-c1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.49
GSK3A P49840 3/20 0.49
CDK1 P06493 2/20 0.45
CCNB2 O95067 1/20 0.44
CCNB1 P14635 1/20 0.44
CCNB3 Q8WWL7 1/20 0.44
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
MAPT P10636 4/20 0.34
PLA2G1B P04054 1/20 0.34
ATG4B Q9Y4P1 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
HSD11B1 P28845 1/20 0.33
BRD4 O60885 1/20 0.32
SCN10A Q9Y5Y9 1/20 0.31
ALDH1A1 P00352 2/20 0.31
FOLH1 Q04609 1/20 0.31
MAPK1 P28482 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1219461 0.98 GSK3B (0.49) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2904015 0.90 GSK3B (0.43) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2910224 0.90 GSK3B (0.42) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2909914 0.90 GSK3B (0.43) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2912175 0.89 GSK3B (0.51) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2906789 0.89 GSK3B (0.47) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2910220 0.88 GSK3B (0.39) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL14400842 0.88 GSK3B (0.51) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2910408 0.88 GSK3B (0.41) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2912808 0.88 GSK3B (0.46) GSK3BGSK3ACDK1CCNB2CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537099-B1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-08-11 EP disclosed